{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:49:05Z","timestamp":1782604145039,"version":"3.54.5"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec id=\"ab-coi220087-4\"><jats:title>Importance<\/jats:title><jats:p>Survivors of blood or marrow transplant (BMT) are at increased risk of subsequent malignant neoplasms (SMNs). Cancers of the gastrointestinal (GI) system are of special interest because their clinical behavior is often aggressive, necessitating early detection by increasing awareness of high-risk populations.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-5\"><jats:title>Objective<\/jats:title><jats:p>To describe the risk of SMNs in the GI tract after BMT.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A cohort study of 6710 individuals who lived at least 2 years after BMT performed between January 1, 1974, and December 31, 2014, at City of Hope, University of Minnesota, or University of Alabama at Birmingham. End of follow-up was March 23, 2020. Data analysis was performed between September 1, 2022, and September 30, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-7\"><jats:title>Exposures<\/jats:title><jats:p>Demographic and clinical factors; therapeutic exposures before or as part of BMT.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Development of SMNs in the GI tract after BMT. Participants self-reported SMNs in the GI tract; these were confirmed with pathology reports, medical records, or both. For deceased patients, death records were used. Standardized incidence ratios determined excess risk of SMNs in the GI tract compared with that of the general population. Fine-Gray proportional subdistribution hazard models assessed the association between risk factors and SMNs in the GI tract.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-9\"><jats:title>Results<\/jats:title><jats:p>The cohort of 6710 individuals included 3444 (51.3%) autologous and 3266 (48.7%) allogeneic BMT recipients. A total of 3917 individuals (58.4%) were male, and the median age at BMT was 46 years (range, 0-78 years). After 62\u202f479 person-years of follow-up, 148 patients developed SMNs in the GI tract. The standardized incidence ratios for developing specific SMNs ranged from 2.1 for colorectal cancer (95% CI, 1.6-2.8; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) to 7.8 for esophageal cancer (95% CI, 5.0-11.6; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Exposure to cytarabine for conditioning (subdistribution hazard ratio [SHR], 3.1; 95% CI, 1.5-6.6) was associated with subsequent colorectal cancer. Compared with autologous BMT recipients, allogeneic BMT recipients with chronic graft-vs-host disease were at increased risk for esophageal cancer (SHR, 9.9; 95% CI, 3.2-30.5). Conditioning with etoposide (SHR, 2.0; 95% CI, 1.1-3.5) and pre-BMT anthracycline exposure (SHR, 5.4; 95% CI, 1.3-23.4) were associated with an increased risk of liver cancer compared with no exposure to the respective agents.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220087-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this cohort study are relevant for oncologists and nononcologists who care for the growing number of survivors of transplant. Awareness of subgroups of survivors of BMT at high risk for specific types of SMNs in the GI tract may influence recommendations regarding modifiable risk factors, as well as individualized screening.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.6569","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T16:03:10Z","timestamp":1674144190000},"page":"376","source":"Crossref","is-referenced-by-count":3,"title":["Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant"],"prefix":"10.1001","volume":"9","author":[{"given":"Andrew","family":"McDonald","sequence":"first","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"},{"name":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Dai","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Meng","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hageman","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richman","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liton","family":"Francisco","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ross","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Balas","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysia","family":"Bosworth","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hok Sreng","family":"Te","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Lennie","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Landier","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"},{"name":"Division of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Salzman","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham"},{"name":"Division of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"coi220087r1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbmt.2013.07.020","article-title":"Prevalence of hematopoietic cell transplant survivors in the United States.","volume":"19","author":"Majhail","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"coi220087r2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"issue":"9","key":"coi220087r3","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","article-title":"Malignant neoplasms following bone marrow transplantation.","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"issue":"10","key":"coi220087r4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7326\/0003-4819-131-10-199911160-00004","article-title":"Malignant neoplasms in long-term survivors of bone marrow transplantation.","volume":"131","author":"Kolb","year":"1999","journal-title":"Ann Intern Med"},{"issue":"26","key":"coi220087r5","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"10","key":"coi220087r6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1200\/JCO.1994.12.10.2187","article-title":"Secondary malignancies after bone marrow transplantation in adults.","volume":"12","author":"Lowsky","year":"1994","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi220087r7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/bmt.2017.4","article-title":"Increased incidence of oral and gastrointestinal secondary cancer after allogeneic hematopoietic stem cell transplantation.","volume":"52","author":"Tanaka","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"coi220087r8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","article-title":"Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients.","volume":"5","author":"Tichelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"coi220087r9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1179\/1607845414Y.0000000154","article-title":"Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction.","volume":"19","author":"Zamora-Ortiz","year":"2014","journal-title":"Hematology"},{"issue":"2","key":"coi220087r10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-018-0290-6","article-title":"Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up.","volume":"54","author":"Martelin","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"coi220087r11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.cmpb.2014.11.009","article-title":"PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression.","volume":"118","author":"Kohl","year":"2015","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"coi220087r12","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2019-000262","article-title":"Variable selection strategies and its importance in clinical prediction modelling.","volume":"8","author":"Chowdhury","year":"2020","journal-title":"Fam Med Community Health"},{"issue":"3","key":"coi220087r13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.v60.3","article-title":"Variable selection\u2014a review and recommendations for the practicing statistician.","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"issue":"5","key":"coi220087r14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/bmt.2014.13","article-title":"Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.","volume":"49","author":"Bilmon","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"coi220087r15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/bmt.2015.63","article-title":"Secondary solid cancer screening following hematopoietic cell transplantation.","volume":"50","author":"Inamoto","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"coi220087r16","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2004-09-3411","article-title":"Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.","volume":"105","author":"Curtis","year":"2005","journal-title":"Blood"},{"issue":"25","key":"coi220087r17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.20.00231","article-title":"Total body irradiation and risk of breast cancer after blood or marrow transplantation: a blood or marrow transplantation survivor study report.","volume":"38","author":"McDonald","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi220087r18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00066-011-2190-1","article-title":"Retrospective, monocentric analysis of late effects after total body irradiation (TBI) in adults.","volume":"187","author":"B\u00f6lling","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"coi220087r19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1200\/JCO.2015.65.0465","article-title":"Anthracyclines and alkylating agents: new risk factors for breast cancer in childhood cancer survivors?","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi220087r20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-156-11-201206050-00002","article-title":"Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.","volume":"156","author":"Henderson","year":"2012","journal-title":"Ann Intern Med"},{"issue":"3","key":"coi220087r21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"coi220087r22","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3748\/wjg.v18.i20.2493","article-title":"Cost-benefit analysis of esophageal cancer endoscopic screening in high-risk areas of China.","volume":"18","author":"Yang","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"5S","key":"coi220087r23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.6004\/jnccn.2018.0052","article-title":"Hepatocellular carcinoma: updates to screening and diagnosis.","volume":"16","author":"Covey","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"coi220087r24","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v25.i13.1550","article-title":"Hepatocellular carcinoma surveillance: an evidence-based approach.","volume":"25","author":"Harris","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"26","key":"coi220087r25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma.","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"coi220087r26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article.","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiat Oncol J"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2800754\/jamaoncology_mcdonald_2023_oi_220087_1678387709.5574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:02:13Z","timestamp":1678978933000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.6569","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}